NEO100 and High-Grade Meningioma
Abroad (travel likely)RecruitingPHASE2
Conditions
Residual, Progressive or Recurrent Grade II or III Meningioma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Southern California, Los Angeles, California, United States
Contact: Principal Investigator (Frances Chow, MD)Sutter Health Research Institute, San Francisco, California, United States
Contact: Principal Investigator (Akanksha Sharma, MD)Saint John Cancer Institute, Santa Monica, California, United States
Contact: Principal Investigator (Naveed Wagle, MD)Tufts Medical Center, Boston, Massachusetts, United States
Contact: Principal Investigator (Soma Sengupta, MD)Baylor Scott and White, Dallas, Texas, United States
Contact: Principal Investigator (Emmanuel Mantilla, MD)
Study leads
Tom Chen, MD, PhD
Study Chair
NeOnc Technologies
Josh Neman
Study Director
NeOnc Technologies Holdings, Inc.